Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
These skin-brightening injections can correct any dark spots or discolouration on the skin
With the support of our experienced team at Infinite Wellness Hormone Specialist, you can embark on a transformative journey to better health
Molecular Identity Developer Innovent Biologics (China) / Eli Lilly partnership Mechanism Dual GLP-1 and glucagon receptor agonist GIP Activation No Administration Weekly subcutaneous Development Stage Phase 3 trials (primarily in China) Glucagon Receptor Pathway The glucagon receptor activation in Mazdutide engages metabolic pathways distinct from GIP: Hepatic metabolism: Glucagon signaling activates liver-based energy expenditure pathways Thermogenesis: Documented effects on energy expenditure in preclinical models Lipid metabolism: Research indicates effects on liver lipid processing Different satiety mechanism: Complementary to GLP-1's central appetite effects Published Research Mazdutide clinical data has been published primarily from Chinese trial populations: Trial Phase Population Key Findings GLORY-1 Phase 3 Chinese adults Metabolic endpoints documented GLORY-2 Phase 3 Chinese adults Glycemic pathway effects documented IBI362 Phase 2 Phase 2 Multiple cohorts Dose-response relationships established Tirzepatide: GLP-1 + GIP Tirzepatide represents the most established dual-agonist compound with full FDA approval and extensive published literature
2022 Apr 1;28(2):559-602
Key takeaways: Unlike FDA-approved GLP-1 medications like Ozempic and Wegovy, dietary supplements like Lemme GLP-1 Daily do not require FDA approval or any data to support their marketing claims
US$ 20.19
US$ 27.79
US$ 21.48
US$ 26.66
US$ 22.31
US$ 24.05
US$ 23.96
US$ 29.14
US$ 21.66
